Rheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Rheumatology, allergology and clinical immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Expert Opin Investig Drugs. 2023 May;32(5):361-371. doi: 10.1080/13543784.2023.2207737. Epub 2023 May 3.
Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting about one-third of subjects with psoriasis. Several treatment modalities targeting Janus Kinase pathways and intracellular inflammatory cascade are now available and under clinical investigation to treat this disease.
This review describes ongoing and recently completed phase 2 and 3 randomized clinical trials (RCTs) evaluating the efficacy and safety of approved JAK (Tofacitinib and Upadacitinib) and investigational JAK inhibitors (JAK1 inhibitors: Filgotinib and Ivarmacitinib (SHR0302); TYK2 inhibitors: Brepocitinib (PF-06700841) Deucravacitinib (BMS-986165), and NDI-034858) in PsA through February 2023.
Current standard of care has significantly improved the quality of life in PsA. Recently approved JAK inhibitors for PsA have addressed many of the unmet needs of PsA, particularly of those with severe phenotypes. Preliminary results from several RCTs have reported good and fast efficacy and an acceptable safety profile of investigational JAK inhibitors in PsA. Additional clinical trials and long-term outcome data on these agents are necessary for increasing available therapeutic options for PsA.
银屑病关节炎（PsA）是一种慢性炎症性疾病，约影响三分之一的银屑病患者。目前有多种针对 Janus 激酶途径和细胞内炎症级联的治疗方法，正在进行临床研究以治疗这种疾病。
本文描述了正在进行和最近完成的评估已批准的 JAK（托法替尼和乌帕替尼）和研究性 JAK 抑制剂（JAK1 抑制剂：Filgotinib 和 Ivarmacitinib（SHR0302）；TYK2 抑制剂：Brepocitinib（PF-06700841）、Deucravacitinib（BMS-986165）和 NDI-034858）在 PsA 中的疗效和安全性的 2 期和 3 期随机临床试验（RCT），截至 2023 年 2 月。
目前的标准治疗方法显著提高了 PsA 的生活质量。最近批准的用于治疗 PsA 的 JAK 抑制剂满足了 PsA 的许多未满足的需求，特别是那些严重表型的患者。几项 RCT 的初步结果报告了研究性 JAK 抑制剂在 PsA 中的良好和快速疗效以及可接受的安全性。需要更多的临床试验和这些药物的长期结果数据，以增加 PsA 的治疗选择。
